Zydus Lifesciences Ltd received US FDA approval for bosentan tablets for oral suspension, 32 mg, for pulmonary arterial hypertension (PAH) treatment. Shares of Zydus Lifesciences Ltd ended marginally higher on Wednesday, February 18, by 0.65% at ₹912.50 on the NSE.
